Department of Cardiology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Wuhou District, Chengdu City, 600713, Sichuan Province, People's Republic of China.
Department of Cardiology, Longquanyi First People's Hospital, Chengdu, China.
J Interv Card Electrophysiol. 2023 Mar;66(2):373-379. doi: 10.1007/s10840-022-01327-5. Epub 2022 Aug 1.
Pneumopericardium is a rare complication of epicardial ablation after dry pericardiocentesis to treat ventricular arrhythmia (VA); its exact clinical effects on patients are still unclear. The purpose of this study was to evaluate the clinical effects of pneumopericardium during epicardial ablation on patients with VA.
Patients with VA who underwent epicardial catheter ablation under local anesthesia at West China Hospital of Sichuan University from August 2012 to January 2022 were enrolled in this study. The incidence of pneumopericardium was investigated. The occurrence of major adverse cardiovascular events (MACEs) was evaluated 1 year after the operation.
A total of 86 VA patients were included in the study. Twenty-two cases had pneumopericardium, with an incidence rate of 25.6%, and 12 (54.55%) patients complained of dyspnea during the procedure with an average occurrence time of 5.4 ± 3.2 min after pericardiocentesis. The blood pressure (BP) decreased significantly, with the mean BP dropping from 119.8/73.2 to 103.5/64.9 mmHg (p < 0.001). None of the cases progressed to tension pneumopericardium. Postoperative follow-up with a median period of 411 days showed that the incidence rate of major adverse cardiovascular events (MACEs), including the composite endpoints of all-cause death, rehospitalization for heart failure, and tachyarrhythmia events, was 36.4% (n = 8) in the pneumopericardium group and 35.5% (n = 23) in the non-pneumopericardium group. The Kaplan-Meier survival analysis showed that there was no statistically significant difference in the incidence of MACEs between the two groups (p = 0.28).
The incidence of pneumopericardium during epicardial ablation was relatively high. However, if recognized early and managed properly, it is unlikely to progress to tension pneumopericardium. The occurrence of pneumopericardium during the procedure may not significantly affect the long-term prognosis of patients.
心包积气是经皮心包穿刺术治疗室性心律失常(VA)后行心外膜消融术的罕见并发症,其对患者的具体临床影响尚不清楚。本研究旨在评估心外膜消融术中心包积气对 VA 患者的临床影响。
回顾性分析 2012 年 8 月至 2022 年 1 月在四川大学华西医院行局部麻醉下心外膜导管消融术的 VA 患者。研究心包积气的发生率,评估术后 1 年主要不良心血管事件(MACEs)的发生情况。
共纳入 86 例 VA 患者,其中 22 例发生心包积气,发生率为 25.6%,12 例(54.55%)患者在心包穿刺术后出现呼吸困难,平均发生时间为心包穿刺后 5.4±3.2min。血压(BP)显著下降,平均 BP 从 119.8/73.2mmHg 降至 103.5/64.9mmHg(p<0.001)。无一例进展为张力性心包积气。中位随访 411 天,心包积气组和无心包积气组的主要不良心血管事件(MACEs)发生率,包括全因死亡、心力衰竭再住院和心动过速事件的复合终点,分别为 36.4%(n=8)和 35.5%(n=23)。Kaplan-Meier 生存分析显示两组 MACEs 发生率无统计学差异(p=0.28)。
心外膜消融术中心包积气的发生率相对较高,但如果早期识别并适当处理,不太可能进展为张力性心包积气。术中发生心包积气可能不会对患者的长期预后产生显著影响。